Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 15/2008

01.10.2008 | Review Article

Pathogenesis and Treatment of Pruritus in Cholestasis

verfasst von: Andreas E. Kremer, MD, Ulrich Beuers, Ronald P. J. Oude-Elferink, Thomas Pusl

Erschienen in: Drugs | Ausgabe 15/2008

Einloggen, um Zugang zu erhalten

Abstract

Pruritus is an enigmatic, seriously disabling symptom accompanying cholestatic liver diseases and a broad range of other disorders. Most recently, novel itchspecificneuronal pathways, itch mediators and their relevant receptors have been identified. In addition, new antipruritic therapeutic strategies have been developed and/or are under evaluation. This review highlights recent experimental and clinical findings focusing on the pathogenesis and actual treatment of pruritus in cholestatic liver disease. Evidence-based therapeutic recommendations, including the use of anion exchange resins cholestyramine, colestipol and colesevelam, the microsomal enzyme inducer rifampicin, the opioid receptor antagonists naltrexone and naloxone, and the serotonin reuptake inhibitor sertraline, are provided.
Literatur
1.
Haffenreffer S. Nosodochium, in quo cutis, eique adaerentium partium, affectus omnes, singulari methodo, et cognoscendi e curandi fidelisime traduntur. Ulmae: Kuhnen; 1660: 98–102
2.
Stander S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87(4): 291–4PubMedCrossRef
3.
Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000 Apr; 31(4): 1005–13
4.
Swain MG. Pruritus and lethargy in the primary biliary cirrhosis patient. In: Neuberger J, editor. Primary biliary cirrhosis. Eastbourne: West End Studios, 1999: 75–81
5.
Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14(4): 643–55PubMedCrossRef
6.
Pusl T, Beuers U. Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006 Jun 14; 12(22): 3487–95PubMed
7.
Lucey MR, Neuberger JM, Williams R. Primary biliary cirrhosis in men. Gut 1986; 27(11): 1373–6PubMedCrossRef
8.
Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995; 108(5): 1582–8PubMedCrossRef
9.
10.
11.
Elias E, Burra P. Primary biliary cirrhosis: symptomatic treatment. J Gastroenterol Hepatol 1991 Nov–Dec; 6(6): 570–3PubMedCrossRef
12.
Elias E. Liver transplantation. J R Coll Physicians Lond 1993; 27(3): 224–32PubMed
13.
Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001; 13(11): 1393–4PubMedCrossRef
14.
Savin JA, Paterson WD, Oswald I. Scratching during sleep. Lancet 1973; II(7824): 296–7CrossRef
15.
Stein H, Bijak M, Heerd E, et al. Pruritometer 1: portable measuring system for quantifying scratching as an objective measure of cholestatic pruritus [in German]. Biomed Tech (Berl) 1996; 41(9): 248–52CrossRef
16.
Bijak M, Mayr W, Rafolt D, et al. Pruritometer 2: portable recording system for the quantification of scratching as objective criterion for the pruritus. Biomed Tech (Berl) 2001; 46(5): 137–41CrossRef
17.
Schworer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron [letter]. Lancet 1993; 341(8855): 1277PubMedCrossRef
18.
Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61(1): 33–7PubMedCrossRef
19.
O’Donohue JW, Pereira SP, Ashdown AC, et al. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 2005; 21(8): 1041–5PubMedCrossRef
20.
Jones EA, Molenaar HA, Oosting J. Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology 2007; 54(76): 1196–9PubMed
21.
Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113(4): 1264–9PubMedCrossRef
22.
Villamil AG, Bandi JC, Galdame OA, et al. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med 2005; 118(10): 1160–3PubMedCrossRef
23.
Bergasa NV, McGee M, Ginsburg IH, et al. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology 2006 Nov; 44(5): 1317–23PubMedCrossRef
24.
von Frey M. Zur physiologie des juckreizes. Arch Neerl Physiol 1922; 7: 142–5
25.
26.
Shelley WB, Arthur RP. The neurohistology and neurophysiology of the itch sensation in man. AMA Arch Derm 1957; 76(3): 296–323PubMedCrossRef
27.
McMahon SB, Koltzenburg M. Itching for an explanation. Trends Neurosci 1992; 15(12): 497–501PubMedCrossRef
28.
29.
30.
Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin. J Neurosci 1997; 17(20): 8003–8PubMed
31.
Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001; 4(1): 72–7PubMedCrossRef
32.
Green BG, Shaffer GS. The sensory response to capsaicin during repeated topical exposures: differential effects on sensations of itching and pungency. Pain 1993; 53(3): 323–34PubMedCrossRef
33.
Ikoma A, Steinhoff M, Stander S, et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7(7): 535–47PubMedCrossRef
34.
Davidson S, Zhang X, Yoon CH, et al. The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci 2007; 27(37): 10007–14PubMedCrossRef
35.
Darsow U, Scharein E, Simon D, et al. New aspects of itch pathophysiology: component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire’. Int Arch Allergy Immunol 2001; 124(1-3): 326–31PubMedCrossRef
36.
Atanassoff PG, Brull SJ, Zhang J, et al. Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens Mot Res 1999; 16(4): 291–8PubMedCrossRef
37.
38.
Ikoma A, Rukwied R, Stander S, et al. Neurophysiology of pruritus: interaction of itch and pain. Arch Dermatol 2003; 139(11): 1475–8PubMedCrossRef
39.
40.
Darsow U, Drzezga A, Frisch M, et al. Processing of histamine-induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J Invest Dermatol 2000; 115(6): 1029–33PubMedCrossRef
41.
Mochizuki H, Tashiro M, Kano M, et al. Imaging of central itch modulation in the human brain using positron emission tomography. Pain 2003; 105(1-2): 339–46PubMedCrossRef
42.
Drzezga A, Darsow U, Treede RD, et al. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain 2001; 92(1–2): 295–305PubMedCrossRef
43.
Mochizuki H, Sadato N, Saito DN, et al. Neural correlates of perceptual difference between itching and pain: a human fMRI study. Neuroimage 2007; 36(3): 706–17PubMedCrossRef
44.
Yosipovitch G, Duque MI, Fast K, et al. Scratching and noxious heat stimuli inhibit itch in humans: a psychophysical study. Br J Dermatol 2007; 156(4): 629–34PubMedCrossRef
45.
Yosipovitch G, Ishiuji Y, Patel TS, et al. The brain processing of scratching. J Invest Dermatol 2008 Jul; 128(7): 1806–11PubMedCrossRef
46.
Paus R, Schmelz M, Biro T, et al. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006; 116(5): 1174–86PubMedCrossRef
47.
Steinhoff M, Bienenstock J, Schmelz M, et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006; 126(8): 1705–18PubMedCrossRef
48.
Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990; 11(5): 884–7PubMedCrossRef
49.
Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis 2008; 12(2): 385–406PubMedCrossRef
50.
Bergasa NV. Update on the treatment of the pruritus of cholestasis. Clin Liver Dis 2008; 12(1): 219–34PubMedCrossRef
51.
52.
Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966; 50(3): 323–32PubMed
53.
Stapelbroek JM, van Erpecum KJ, Klomp LW, et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 2006; 43(1): 51–3PubMedCrossRef
54.
Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006 Jul; 44(1): 280–1PubMedCrossRef
55.
Huet PM, Rautureau M, Dhumeaux D, et al. The effects of biliary drainage in cholestatic hepatitis [in French]. Rev Med Chir Mal Foie 1970; 45(5): 271–8PubMed
56.
Rupp N. Indications and results of percutaneous transhepatic bile-duct drainage [in German]. Chirurg 1979; 50(4): 233–8PubMed
57.
Hall RI, Denyer ME, Chapman AH. Percutaneous-endoscopic placement of endoprostheses for relief of jaundice caused by inoperable bile duct strictures. Surgery 1990; 107(2): 224–7PubMed
58.
Jones EA, Bergasa NV. Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can J Gastroenterol 2000; 14(1): 33–40PubMed
59.
Mamianetti A, Tripodi V, Vescina C, et al. Serum bile acids and pruritus in hemodialysis patients. Clin Nephrol 2000; 53(3): 194–8PubMed
60.
Jimenez F, Monte MJ, El-Mir MY, et al. Chronic renal failure-induced changes in serum and urine bile acid profiles. Dig Dis Sci 2002; 47(11): 2398–406PubMedCrossRef
61.
Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. Gut 1972; 13(3): 201–6PubMedCrossRef
62.
Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus. Gastroenterology 1977; 73(5): 1125–30PubMed
63.
Freedman MR, Holzbach RT, Ferguson DR. Pruritus in cholestasis: no direct causative role for bile acid retention. Am J Med 1981; 70(5): 1011–6PubMedCrossRef
64.
Bartholomew TC, Summerfield JA, Billing BH, et al. Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectrometry. Clin Sci (Lond) 1982; 63(1): 65–73
65.
Silverberg DS, Iaina A, Reisin E, et al. Cholestyramine in uraemic pruritus. Br Med J 1997 Mar 19; 1(6063): 752–3CrossRef
66.
Chanarin I, Szur L. Relief of intractable pruritis in polycythaemia rubra vera with cholestyramine [letter]. Br J Hematol 1975 Apr; 29(4): 669–70CrossRef
67.
Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003; 28(2): 139–68PubMedCrossRef
68.
Melcangi RC, Garcia-Segura LM, Mensah-Nyagan AG. Neuroactive steroids: state of the art and new perspectives. Cell Mol Life Sci 2008; 65(5): 777–97PubMedCrossRef
69.
Park-Chung M, Malayev A, Purdy RH, et al. Sulfated and unsulfated steroids modulate gamma-aminobutyric acid A receptor function through distinct sites. Brain Res 1999; 830(1): 72–87PubMedCrossRef
70.
Wu FS, Gibbs TT, Farb DH. Inverse modulation of gamma-aminobutyric acid- and glycine-induced currents by progesterone. Mol Pharmacol 1990; 37(5): 597–602PubMed
71.
Park-Chung M, Wu FS, Purdy RH, et al. Distinct sites for inverse modulation of N-methyl-D-aspartate receptors by sulfated steroids. Mol Pharmacol 1997; 52(6): 1113–23PubMed
72.
Weaver Jr CE, Marek P, Park-Chung M, et al. Neuroprotective activity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997; 94(19): 10450–4PubMedCrossRef
73.
Weaver Jr CE, Park-Chung M, Gibbs TT, et al. 17β-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res 1997; 761(2): 338–41PubMedCrossRef
74.
Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999; 22(9): 410–6PubMedCrossRef
75.
Wetzel CH, Hermann B, Behl C, et al. Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor. Mol Endocrinol 1998; 12(9): 1441–51PubMedCrossRef
76.
Bullock AE, Clark AL, Grady SR, et al. Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes. J Neurochem 1997; 68(6): 2412–23PubMedCrossRef
77.
Chen SC, Wu FS. Mechanism underlying inhibition of the capsaicin receptor-mediated current by pregnenolone sulfate in rat dorsal root ganglion neurons. Brain Res 2004; 1027(1–2): 196–200PubMedCrossRef
78.
Pathirathna S, Brimelow BC, Jagodic MM, et al. New evidence that both T-type calcium channels and GABAA channels are responsible for the potent peripheral analgesic effects of 5alpha-reduced neuroactive steroids. Pain 2005; 114(3): 429–43PubMedCrossRef
79.
Chen SC, Liu BC, Chen CW, et al. Intradermal pregnenolone sulfate attenuates capsaicin-induced nociception in rats. Biochem Biophys Res Commun 2006; 349(2): 626–33PubMedCrossRef
80.
Green AD, Young KK, Lehto SG, et al. Influence of genotype, dose and sex on pruritogen-induced scratching behavior in the mouse. Pain 2006; 124(1-2): 50–8PubMedCrossRef
81.
Kancheva R, Hill M, Cibula D, et al. Relationships of circulating pregnanolone isomers and their polar conjugates to the status of sex, menstrual cycle, and pregnancy. J Endocrinol 2007; 195(1): 67–78PubMedCrossRef
82.
Reyes H, Sjovall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann Med 2000 Mar; 32(2): 94–106PubMedCrossRef
83.
84.
Glantz A, Reilly SJ, Benthin L, et al. Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology 2008; 47(2): 544–51PubMedCrossRef
85.
Ahboucha S, Pomier-Layrargues G, Vincent C, et al. Reduced plasma dehydroepiandrosterone sulfate levels are significantly correlated with fatigue severity in patients with primary biliary cirrhosis. Neurochem Int 2008; 52(4–5): 569–74PubMedCrossRef
86.
Quist RG, Ton-Nu HT, Lillienau J, et al. Activation of mast cells by bile acids. Gastroenterology 1991; 101(2): 446–56PubMed
87.
Clements WD, O’Rourke DM, Rowlands BJ, et al. The role of mast cell activation in cholestatic pruritus. Agents Actions 1994; 41: C30–1PubMedCrossRef
88.
Rioux KP, Sharkey KA, Wallace JL, et al. Hepatic mucosal mast cell hyperplasia in rats with secondary biliary cirrhosis. Hepatology 1996; 23(4): 888–95PubMedCrossRef
89.
Gittlen SD, Schulman ES, Maddrey WC. Raised histamine concentrations in chronic cholestatic liver disease. Gut 1990; 31(1): 96–9PubMedCrossRef
90.
Beck PW, Handwerker HO. Bradykinin and serotonin effects on various types of cutaneous nerve fibers. Pflugers Arch 1974; 347(3): 209–22PubMedCrossRef
91.
92.
Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res 1992; 597(2): 331–8PubMedCrossRef
93.
94.
Weisshaar E, Ziethen B, Gollnick H. Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? Inflamm Res 1997; 46(10): 412–6PubMedCrossRef
95.
Inagaki N, Nagao M, Igeta K, et al. Scratching behavior in various strains of mice. Skin Pharmacol Appl Skin Physiol 2001; 14(2): 87–96PubMedCrossRef
96.
Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98(12): 2736–41PubMedCrossRef
97.
Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45(3): 666–74PubMedCrossRef
98.
Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115(11): 1366–7PubMedCrossRef
99.
Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297(6662): 1501–4PubMedCrossRef
100.
Spivey JR, Jorgensen RA, Gores GJ, et al. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 1994 Nov; 89(11): 2028–32PubMed
101.
Swain MG, Rothman RB, Xu H, et al. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992; 103(2): 630–5PubMed
102.
Bergasa NV, Vergalla J, Swain MG, et al. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996; 16(5): 298–302PubMed
103.
Jones EA, Bergasa NV. The pruritus of cholestasis and the opioid system. JAMA 1992; 268(23): 3359–62PubMedCrossRef
104.
Bergasa NV, Sabol SL, Young 3rd WS, et al. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995; 268 (2 Pt 1): G346–54PubMed
105.
Bergasa NV, Liau S, Homel P, et al. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002; 22(2): 107–13PubMedCrossRef
106.
Marzioni M, Svegliati Baroni G, Alpini G, et al. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol 2007; 46(4): 583–6PubMedCrossRef
107.
Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988; 33(2): 149–60PubMedCrossRef
108.
Thomas DA, Williams GM, Iwata K, et al. Effects of central administration of opioids on facial scratching in monkeys. Brain Res 1992; 585(1–2): 315–7PubMedCrossRef
109.
Bergasa NV, Thomas DA, Vergalla J, et al. Plasma from patients with the pruritus of cholestasis induces opioid receptormediated scratching in monkeys. Life Sci 1993; 53(16): 1253–7PubMedCrossRef
110.
Bergasa NV, Rothman RB, Vergalla J, et al. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 1992; 15(1–2): 220–4PubMedCrossRef
111.
Nelson L, Vergnolle N, D’Mello C, et al. Endogenous opioidmediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J Hepatol 2006; 44(6): 1141–9PubMedCrossRef
112.
Bergasa NV, Talbot TL, Ailing DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102(2): 544–9PubMed
113.
Bergasa NV, Ailing DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind, randomized, controlled trial. Ann Intern Med 1995; 123(3): 161–7PubMed
114.
Carson KL, Tran TT, Cotton P, et al. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996; 91(5): 1022–3PubMed
115.
Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27(3): 679–84PubMedCrossRef
116.
Terg R, Coronel E, Sorda J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37(6): 717–22PubMedCrossRef
117.
Mansour-Ghanaei F, Taheri A, Froutan H, et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125–8PubMed
118.
Summerfield JA. Naloxone modulates the perception of itch in man. Br J Clin Pharmacol 1980; 10(2): 180–3PubMedCrossRef
119.
Kamei J, Nagase H. Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 2001; 418(1–2): 141–5PubMedCrossRef
120.
Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002; 435(2-3): 259–64PubMedCrossRef
121.
Wikstrom B, Geliert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005; 16(12): 3742–7PubMedCrossRef
122.
Bergasa NV. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am 2006; 35(1): 113–23PubMedCrossRef
123.
Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007; 448(7154): 700–3PubMedCrossRef
124.
Bodo E, Kovacs I, Telek A, et al. Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. J Invest Dermatol 2004; 123(2): 410–3PubMedCrossRef
125.
Stander S, Moormann C, Schumacher M, et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 2004; 13(3): 129–39PubMedCrossRef
126.
Shin J, Cho H, Hwang SW, et al. Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci U S A 2002; 99(15): 10150–5PubMedCrossRef
127.
Kim BM, Lee SH, Shim WS, et al. Histamine-induced Ca(2+) influx via the PLA(2)/lipoxygenase/TRPVl pathway in rat sensory neurons. Neurosci Lett 2004; 361(1–3): 159–62PubMedCrossRef
128.
Shim WS, Tak MH, Lee MH, et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 2007; 27(9): 2331–7PubMedCrossRef
129.
Dvorak M, Watkinson A, McGlone F, et al. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003; 52(6): 238–45PubMed
130.
Binzen U, Greffrath W, Hennessy S, et al. Co-expression of the voltage-gated potassium channel Kv1.4 with transient receptor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat dorsal root ganglion neurons. Neuroscience 2006; 142(2): 527–39PubMedCrossRef
131.
Stander S, Schmelz M, Metze D, et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005; 38(3): 177–88PubMedCrossRef
132.
Ibrahim MM, Porreca F, Lai J, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 2005; 102(8): 3093–8PubMedCrossRef
133.
Hermann H, Petrocellis L, Bisogno T, et al. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci 2003; 60(3): 607–16PubMedCrossRef
134.
Borgeat A, Wilder-Smith OH, Saiah M, et al. Subhypnotic doses of propofol relieve pruritus induced by epidural and intrathecal morphine. Anesthesiology 1992; 76(4): 510–2PubMedCrossRef
135.
Szarvas S, Harmon D, Murphy D. Neuraxial opioid-induced pruritus: a review. J Clin Anesth 2003; 15(3): 234–9PubMedCrossRef
136.
Borgeat A, Wilder-Smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993; 104(1): 244–7PubMed
137.
Prieto LN. The use of midazolam to treat itching in a terminally ill patient with biliary obstruction. J Pain Symptom Manage 2004; 28(6): 531–2PubMedCrossRef
138.
Bergasa NV, Ailing DW, Vergalla J, et al. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994; 20(1): 85–90PubMedCrossRef
139.
Dehpour AR, Sadeghipour HR, Nowroozi A, et al. The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum Psychopharmacol 2000; 15(6): 423–8PubMedCrossRef
140.
Hasanein P, Parviz M, Keshavarz M, et al. Modulation of cholestasis-induced antinociception in rats by two NMDA receptor antagonists: MK-801 and magnesium sulfate. Eur J Pharmacol 2007; 554(2–3): 123–7PubMedCrossRef
141.
Stander S, Streit M, Darsow U, et al. AWMF-leitlinie: diagnostisches und therapeutisches vorgehen bei chronischem pruritus. JDDG 2006; 4: 350–70PubMedCrossRef
142.
Duncan JS, Kennedy HJ, Triger DR. Treatment of pruritus due to chronic obstructive liver disease [letter]. BMJ (Clin Res Ed) 1984; 289(6436): 22CrossRef
143.
Di Padova C, Tritapepe R, Rovagnati P, et al. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 1984; 6(12): 773–6PubMed
144.
Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005 Sep; 129(3): 894–901PubMedCrossRef
145.
Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin: results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94(2): 488–93PubMed
146.
Bachs L, Pares A, Elena M, et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989 Mar 18; I(8638): 574–6CrossRef
147.
Woolf GM, Reynolds TB. Failure of rifampin to relieve pruritus in chronic liver disease. J Clin Gastroenterol 1990 Apr 12; (2): 174–7
148.
Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991; 36(2): 216–20PubMedCrossRef
149.
Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10(10): 865–70PubMedCrossRef
150.
Ribalta J, Reyes H, Gonzalez MC, et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology 1991; 13(6): 1084–9PubMed
151.
Roncaglia N, Locatelli A, Arreghini A, et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004; 111(1): 17–21PubMedCrossRef
152.
Binder T, Salaj P, Zima T, et al. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006; 34(5): 383–91PubMedCrossRef
153.
Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997 Dec; 27(6): 1022–8PubMedCrossRef
154.
Batta AK, Salen G, Mirchandani R, et al. Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol 1993; 88(5): 691–700PubMed
155.
Poupon RE, Chretien Y, Poupon R, et al. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993 Apr; 17(4): 599–604PubMedCrossRef
156.
Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997 Sep; 113(3): 884–90PubMedCrossRef
157.
Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006 Jun; 3(6): 318–28PubMedCrossRef
158.
Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid: adverse effects and drug interactions. Aliment Pharmacol Ther 2003 Nov 15; 18(10): 963–72PubMedCrossRef
159.
Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336(10): 691–5
160.
Talwalkar JA, Souto E, Jorgensen RA, et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003; 1(4): 297–302PubMedCrossRef
161.
Balistreri WF, Heubi JE, Whitington P, et al. Ursodeoxycholic acid (UDCA) therapy in pediatric hepatobiliary disease [abstract]. Hepatology 1989; 10: 602A
162.
Narkewicz MR, Smith D, Gregory C, et al. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr 1998; 26(1): 49–55PubMedCrossRef
163.
Dinier G, Kocak N, Yuce A, et al. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk J Pediatr 1999; 41(1): 91–8
164.
Datta DV, Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. BMJ 1963; 1(5325): 216–9PubMedCrossRef
165.
Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol 2005; 28(2): 147–57PubMedCrossRef
166.
Rust C, Sauter GH, Oswald M, et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest 2000; 30(2): 135–9PubMedCrossRef
167.
Berg CI. Use of colesevalem hydrochloride as a novel therapeutic agent for the managment of refractory pruritus in chronic liver disease [abstract]. Hepatology 2001; 34: 541A
168.
Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005; 28(3): 249–68PubMedCrossRef
169.
LeCluyse EL. Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact 2001; 134(3): 283–9PubMedCrossRef
170.
Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005 Aug; 129(2): 476–85PubMed
171.
Bachs L, Pares A, Elena M, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992 Jun; 102(6): 2077–80PubMed
172.
Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 1990; 98(4): 1013–6PubMedCrossRef
173.
Yerushalmi B, Sokol RJ, Narkewicz MR, et al. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999; 29(4): 442–7PubMedCrossRef
174.
Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006 Oct; 26(8): 943–8PubMedCrossRef
175.
Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102(7): 1528–36PubMedCrossRef
176.
Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50(3): 436–9PubMedCrossRef
177.
Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 2002; 95(8): 547–52PubMedCrossRef
178.
Schumann R, Hudcova J. Cholestasis of pregnancy, pruritus and 5-hydroxytryptamine 3 receptor antagonists. Acta Obstet Gynecol Scand 2004; 83(9): 861–2PubMed
179.
Zylicz Z, Krajnik M, Sorge AA, et al. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003; 26(6): 1105–12PubMedCrossRef
180.
Neff GW, O’Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002; 97(8): 2117–9PubMedCrossRef
181.
Stander S, Reinhardt HW, Luger TA. Topical cannabinoid agonists: an effective new possibility for treating chronic pruritus [in German]. Hautarzt 2006; 57(9): 801–7PubMedCrossRef
182.
Turner IB, Rawlins MD, Wood P, et al. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther 1994; 8(3): 337–42PubMedCrossRef
183.
Walt RP, Daneshmend TK, Fellows IW, et al. Effect of stanozolol on itching in primary biliary cirrhosis [letter]. BMJ (Clin Res Ed) 1988; 296(6622): 607CrossRef
184.
Hanid MA, Levi AJ. Phototherapy for pruritus in primary biliary cirrhosis [letter]. Lancet 1980; II(8193): 530CrossRef
185.
Cerio R, Murphy GM, Sladen GE, et al. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol 1987; 116(2): 265–7PubMedCrossRef
186.
Bergasa NV, Link MJ, Keogh M, et al. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001; 96(5): 1563–70PubMedCrossRef
187.
Cohen LB, Ambinder EP, Wolke AM, et al. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985; 26(3): 291–4PubMedCrossRef
188.
Macia M, Aviles J, Navarro J, et al. Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med 2003; 114(1): 62–4PubMedCrossRef
189.
Pares A, Cisneros L, Salmeron JM, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99(6): 1105–10PubMedCrossRef
190.
Pusl T, Denk GU, Parhofer KG, et al. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006 Dec; 45(6): 887–91PubMedCrossRef
191.
Emerick KM, Whitington PF. Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002; 35(6): 1501–6PubMedCrossRef
192.
Ng VL, Ryckman FC, Porta G, et al. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2000; 30(2): 152–6PubMedCrossRef
Metadaten
Titel
Pathogenesis and Treatment of Pruritus in Cholestasis
verfasst von
Andreas E. Kremer, MD
Ulrich Beuers
Ronald P. J. Oude-Elferink
Thomas Pusl
Publikationsdatum
01.10.2008
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 15/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200868150-00006

Weitere Artikel der Ausgabe 15/2008

Drugs 15/2008 Zur Ausgabe

Adis Drug Evaluation

Pregabalin

Adis Drug Profile

Ambrisentan

Review Article

Topical Fenticonazole in Dermatology and Gynaecology

Adis Drug Evaluation

Micafungin

Review Article

New Drugs for Type 2 Diabetes Mellitus

Therapy In Practice

The Short-Term Medical Management of Non-Variceal Upper Gastrointestinal Bleeding